Ticarcillin plus clavulanate

Ticarcillin plus clavulanic acid 50mg/kg plus 1.67 mg/kg, q.i.d. i.v. 

Grandis JR, Vickers RM, Rihs JD, et al. Efficacy of topical amoxicillin plus clavulanate-ticarcillin plus clavulanate and clindamycin in contaminated head and neck surgery Effect of antibiotic spectra and duration of therapy. J Infect Dis 1994 170 729-732. 

The combination of piperacillin and tazobactam does not increase the activity of piperacillin against P. aeruginosa because there is resistance due to either chromosomal P-lactamases or decreased permeability of piperacillin into the periplasmic space. Because the currently recommended dose (3 g piperacillin per 375 mg tazobactam every 4 to 8 hours) is less than the recommended dose of piperacillin when used alone for serious infections (3 to 4 g every 4 to 6 hours), concern has been raised that piperacillin-tazobactam may prove ineffective in the treatment of some P. aeruginosa infections that would have responded to piperacillin. The combination of piperacillin plus tazobactam should be equivalent in antimicrobial spectrum to ticarcillin plus clavulanate. 

Similarly, good synergistic effects are found with ticarcillin (7) plus clavulanic acid [36]. In fact, a combination with ticarcillin has very broad spectrum activity because ticarcillin itself shows good activity against organisms producing y5-lactamases poorly inhibited by clavulanic acid. 

Alcoholism Aspiration pneumonia Pneumococcus, K pneumoniae, S. aureus, H influenzae, possibly mouth anaerobes Ticarcillin-clavulanate, piperacillin-tazobactam, plus aminoglycoside carba-penem,e fluoroquinolone ... 

Alcoholism Aspiration pneumonia PneumoaKOj K. pnetmionia S. aureus H inSuenzae, posibly mouth anaerobes Ticarcillin-clavulanate, piperacillintazo-bactarrv plus aminoglycoside carba penerrv fluoroquinolone ... 

The in vivo activity of a combination of clavulanic acid and amoxycillin is shown in Table 6.4 [30]. This -lactamase inhibitory activity, together with useful pharmacokinetic properties, has resulted in the development of Augmentin (potassium clavulanate in combination with amoxycillin) for oral and parenteral use and Timentin (potassium clavulanate plus ticarcillin) for parenteral use, against a wide range of bacterial infections. ... 

Whatever the mechanisms might be, at present it is reasonable to look on clavulanate as the main contributor to the development of hepatotoxicity with co-amoxiclav. Hepatotoxicity has also been reported with clavulanate plus ticarcillin (34). So far, however, there has been no genetic evaluation of patients with hepatotoxic reactions after therapy with clavulanate and ticarcillin. 

Cefepime, ceftazidime, piperacillin-tazobactam, or ticarcillin-clavulanate plus aminoglycoside ... 

Postoperative or posttrauma patients Gram-positive and gram-negative organ isms Nafcillin 2 g IV every 4 hours plus ceftazidime 2 g IV every 8 hours or ticarcillin-clavulanate 3.1 g IV every 4 hours... 

---